Learn More About ReNeuron
Interim Results for the six months ended 30 September 2021
New CTX-iPSC platform data shows potential in Peripheral Nerve Repair
Notice of Results – Investor presentation
Collaboration agreement with UCL
First subject treated at Oxford Eye Hospital in Phase 2a RP trial
at 30-12-2021 2:22:00
15 minute delayed share price from London Stock Exchange provided by Euroland.